Compare · VERX vs VRTX
VERX vs VRTX
Side-by-side comparison of Vertex Inc. (VERX) and Vertex Pharmaceuticals Incorporated (VRTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- VERX operates in Technology, while VRTX operates in Health Care - the two are in different parts of the market.
- VRTX is the larger of the two at $114.63B, about 63.7x VERX ($1.80B).
- Over the past year, VERX is down 67.3% and VRTX is up 2.4% - VRTX leads by 69.8 points.
- VERX has been more active in the news (10 items in the past 4 weeks vs 9 for VRTX).
- Both have 25 recent analyst ratings on file.
- Company
- Vertex Inc.
- Vertex Pharmaceuticals Incorporated
- Price
- $11.10-2.67%
- $451.76-1.60%
- Market cap
- $1.80B
- $114.63B
- 1M return
- -15.72%
- +4.03%
- 1Y return
- -67.33%
- +2.44%
- Industry
- Computer Software: Prepackaged Software
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 1991
- News (4w)
- 10
- 9
- Recent ratings
- 25
- 25
Vertex Inc.
Vertex, Inc. provides tax technology solutions for corporations in retail, communication, leasing, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. The company was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Latest VERX
- Director Destefano David was granted 15,638 shares, increasing direct ownership by 1% to 1,271,155 units (SEC Form 4)
- Director Gayton Bradley M was granted 15,638 shares, increasing direct ownership by 30% to 68,500 units (SEC Form 4)
- Director Saunders Philip Seth was granted 15,638 shares, increasing direct ownership by 45% to 50,606 units (SEC Form 4)
- Director Radcliffe Amanda Westphal was granted 15,638 shares, increasing direct ownership by 11% to 159,030 units (SEC Form 4)
- Director Stamm John Richard was granted 15,638 shares, increasing direct ownership by 92% to 32,685 units (SEC Form 4)
- Director Andersen Eric C. was granted 15,638 shares, increasing direct ownership by 10% to 165,979 units (SEC Form 4)
- Director Thompson Stefanie Westphal was granted 15,638 shares, increasing direct ownership by 30% to 66,995 units (SEC Form 4)
- Director Mendola Mark J was granted 15,638 shares, increasing direct ownership by 294% to 20,965 units (SEC Form 4)
- Director Destefano David sold $82,365 worth of shares (6,460 units at $12.75) (SEC Form 4)
- Vertex to Present at the 46th Annual William Blair Growth Stock Conference
Latest VRTX
- EVP and CMO Bozic Carmen sold $1,827,900 worth of shares (4,062 units at $450.00) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 16,953 units (SEC Form 4)
- Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
- EVP and CMO Bozic Carmen sold $785,250 worth of shares (1,745 units at $450.00) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 21,015 units (SEC Form 4)
- EVP and Chief Legal Officer Liu Joy sold $364,245 worth of shares (828 units at $439.91) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 19,959 units (SEC Form 4)
- Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
- EVP and CMO Bozic Carmen sold $888,300 worth of shares (1,974 units at $450.00) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 22,760 units (SEC Form 4)
- Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
- Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
- Truist resumed coverage on Vertex Pharma with a new price target
- Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults